聚光科技(300203.SZ)：擬同意譜聚醫療引入財務投資人紅杉資本等等
格隆匯6月24日丨聚光科技(300203.SZ)公佈，杭州譜聚醫療科技有限公司為公司的控股子公司，主營業務為臨牀微量元素和小分子代謝物檢測相關業務，主要包括醫用單杆或三重四極杆電感耦合等離子體質譜微量元素分析儀、三重四極杆液相色譜串聯質譜小分子代謝物診斷系統及其配套樣本全自動處理系統，和以上臨牀儀器相應的體外診斷試劑盒的生產、研發、銷售。
為促進控股子公司譜聚醫療未來業務發展，同時充實其資本實力，公司擬同意譜聚醫療引入財務投資人。
公司擬對新進財務投資人作出以下股權安排：
1、財務投資人受讓譜聚醫療部分股權：
譜聚醫療現有股東浙江盛域投資管理有限公司(“盛域投資”)持有譜聚醫療RMB 4,615,384.62元的註冊資本，現擬將其中合計RMB 854,700.86元的註冊資本以合計RMB 4000萬元的對價轉讓給深圳市紅杉瀚辰股權投資合夥企業(有限合夥)(“紅杉瀚辰”)、太嘉杉健康產業股權投資基金(上海)合夥企業(有限合夥)(“太嘉杉”，和“紅杉瀚辰”合稱為“紅杉資本”)、山東惠遠華檢醫療投資合夥企業(有限合夥)(“山東惠遠”)、杭州金械投資合夥企業(有限合夥(“杭州金械”)、深圳市拓盈私募股權基金管理有限公司(“深圳拓盈”)、【聚光合夥】(為聚光科技管理層跟投平台，尚待董事會會議審議通過之後設立，“聚光合夥”)，此次轉讓完成後，盛域投資剩餘持有譜聚醫療RMB 3,760,683.76元的註冊資本。譜聚醫療其他現有股東均放棄優先受讓權。
2、財務投資人增資
上述轉讓事項完成後，紅杉瀚辰等6家財務投資人擬向譜聚醫療合計增資RMB 1.85億元，其中RMB 3,016,591.25元計入譜聚醫療註冊資本，餘下RMB 181,983,408.75元計入譜聚醫療資本公積。譜聚醫療其他現有股東均放棄優先認購權。
上述交易完成後，譜聚醫療的註冊資本由RMB 17,094,017.10元增至RMB 20,110,608.35元，公司通過控股子公司杭州譜育科技發展有限公司持有譜聚醫療的股權比例由58.50%變更為49.72%，譜聚醫療仍屬於公司合併報表範圍內的控股子公司。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
